Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine

Main Article Content

O.P. Nechai
D.M. Kvitka
P.O. Lischynskyi
R.M. Sichinava


It is known that overweight leads to a number of chronic diseases and affects life expectancy. From 1975 to 2016, the pre­valence of overweight in adults (body mass index ≥ 25 kg/m2) increased from almost 21 % in men and 24 % in women to about 40 % in people of both sexes, and the prevalence of obesity (body mass index ≥ 30 kg/m2) quadrupled in men, from 3 to 12 %, and more than doubled in women, from 7 to 16 %. In 2012, overweight was found in approximately 3.9 % of all cancer patients (544,300 cases), ranging from 1 % in low-income countries to 8 % in some high-income Western countries. Recent decades have shown an increase in the population with overweight and a simultaneous increase in the incidence of malignancies, including thyroid cancer. All researchers reporting association between obesity and thyroid cancer are unanimous in calling for further researches that will lead to an understanding of the underlying mechanisms of this link. To date, possible mechanisms of development are assessed as complex and include numerous factors at both the systemic and cellular levels. Disorders of insulin metabolism, adipokines, inflammatory processes and sex hormones contribute to the influence of obesity on the development of cancer and its progression. The results of the review of the researches allow drawing a conclusion about existence of connection between overweight and the increased risk of tumor process, including development of thyroid cancer. At the same time, the presence of various hypotheses about the pathophysiolo­gical mechanisms and patterns of the relationship between obesity and the tumor development, most likely, indicates the multifactorial nature of this process and encourages its further in-depth study.

Article Details

How to Cite
Nechai, O., D. Kvitka, P. Lischynskyi, and R. Sichinava. “Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 16, no. 3, Apr. 2020, pp. 272-7, doi:10.22141/2224-0721.16.3.2020.205278.
Literature Review


World Health Organization. Obesity and Overweight Fact Sheet. Geneva, Switzerland: World Health Organization; 2018. Available from:

GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377(1):13‐27. doi:10.1056/NEJMoa1614362.

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627‐2642. doi:10.1016/S0140-6736(17)32129-3.

Hruby A, Hu FB. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics. 2015;33(7):673‐689. doi:10.1007/s40273-014-0243-x.

Dobbs R, Sawers C, Thompson F, et al. Overcoming Obesity: An Initial Economic Analysis. New York: McKinsey Global Institute; 2014. Available from:

Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794‐798. doi:10.1056/NEJMsr1606602.

World Cancer Research Fund; American Institute for Cancer Research. Continuous Update Project Report 2018. Body Fatness and Weight Gain and the Risk of Cancer. London, UK: World Cancer Research Fund International; 2018. Available from:

Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6(6):e6‐e15. doi:10.1016/S2213-8587(18)30150-5.

Bandera EV, Fay SH, Giovannucci E, et al. The use and interpretation of anthropometric measures in cancer epidemiology: A perspective from the world cancer research fund international continuous update project. Int J Cancer. 2016;139(11):2391‐2397. doi:10.1002/ijc.30248.

Hu F. Chapter 5: Measurements of Adiposity and Body Composition. In: Hu F, ed. Obesity Epidemiology. New York: Oxford University Press; 2008. 53-83 pp.

Iyengar NM, Zhou XK, Gucalp A, et al. Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. Clin Cancer Res. 2016;22(9):2283‐2289. doi:10.1158/1078-0432.CCR-15-2239.

Mullooly M, Yang HP, Falk RT, et al. Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients. Breast Cancer Res. 2017;19(1):8. doi:10.1186/s13058-016-0791-4.

Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10(11):656‐665. doi:10.1038/nrgastro.2013.183.

Sijens PE, Edens MA, Bakker SJ, Stolk RP. MRI-determined fat content of human liver, pancreas and kidney. World J Gastroenterol. 2010;16(16):1993‐1998. doi:10.3748/wjg.v16.i16.1993.

Hori M, Takahashi M, Hiraoka N, et al. Association of pancreatic Fatty infiltration with pancreatic ductal adenocarcinoma. Clin Transl Gastroenterol. 2014;5(3):e53. doi:10.1038/ctg.2014.5.

Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15(8):484‐498. doi:10.1038/nrc3967.

Thanassoulis G, Massaro JM, Hoffmann U, et al. Prevalence, distribution, and risk factor correlates of high pericardial and intrathoracic fat depots in the Framingham heart study. Circ Cardiovasc Imaging. 2010;3(5):559‐566. doi:10.1161/CIRCIMAGING.110.956706.

UK BioBank. Imaging Data. Stockport, UK: UK BioBank; 2018.

Ma J, Huang M, Wang L, Ye W, Tong Y, Wang H. Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies. Med Sci Monit. 2015;21:283‐291. doi:10.12659/MSM.892035.

Kwon H, Han KD, Park CY. Weight change is significantly associated with risk of thyroid cancer: A nationwide population-based cohort study. Sci Rep. 2019;9(1):1546. doi:10.1038/s41598-018-38203-0.

He Q, Sun H, Li F, Liang N. Obesity and risk of differentiated thyroid cancer: A large-scale case-control study. Clin Endocrinol (Oxf). 2019;91(6):869‐878. doi:10.1111/cen.14091.

Kitahara CM, McCullough ML, Franceschi S, et al. Anthropometric Factors and Thyroid Cancer Risk by Histological Subtype: Pooled Analysis of 22 Prospective Studies. Thyroid. 2016;26(2):306‐318. doi:10.1089/thy.2015.0319.

Kim KN, Hwang Y, Kim KH, et al. Adolescent overweight and obesity and the risk of papillary thyroid cancer in adulthood: a large-scale case-control study. Sci Rep. 2020;10(1):5000. doi:10.1038/s41598-020-59245-3.

Lohmann AE, Goodwin PJ, Chlebowski RT, Pan K, Stambolic V, Dowling RJ. Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome. J Clin Oncol. 2016;34(35):4249‐4255. doi:10.1200/JCO.2016.69.6187.

Hopkins BD, Goncalves MD, Cantley LC. Obesity and Cancer Mechanisms: Cancer Metabolism. J Clin Oncol. 2016;34(35):4277‐4283. doi:10.1200/JCO.2016.67.9712.

Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev. 2015;95(3):727‐748. doi:10.1152/physrev.00030.2014.

Keum N, Song M, Giovannucci ED, Eliassen AH. Chapter 20: Obesity and body composition. In: Thun M, Linet MS, Cerhan JR, Haiman CA, Shottenfeld D, eds. Cancer Epidemiology and Prevention. 4th ed. New York: Oxford University Press; 2017. 351-376 pp. doi:10.1093/oso/9780190238667.003.0020.

Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346‐1353. doi:10.1016/S0140-6736(04)16044-3.

Green J, Cairns BJ, Casabonne D, et al. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 2011;12(8):785‐794. doi:10.1016/S1470-2045(11)70154-1.

Carreras-Torres R, Johansson M, Gaborieau V, et al. The Role of Obesity, Type 2 Diabetes, and Metabolic Factors in Pancreatic Cancer: A Mendelian Randomization Study. J Natl Cancer Inst. 2017;109(9):djx012. doi:10.1093/jnci/djx012.

Nead KT, Sharp SJ, Thompson DJ, et al. Evidence of a Causal Association Between Insulinemia and Endometrial Cancer: A Mendelian Randomization Analysis. J Natl Cancer Inst. 2015;107(9):djv178. doi:10.1093/jnci/djv178.

Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674‐1685. doi:10.2337/dc10-0666.

Bulun SE, Chen D, Moy I, Brooks DC, Zhao H. Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab. 2012;23(2):83‐89. doi:10.1016/j.tem.2011.10.003.

Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218‐1226. doi:10.1093/jnci/djg022.

Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63(5):800‐809. doi:10.1016/j.eururo.2012.11.013.

Williams G. Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-α and GPER signalling. Mol Cell Endocrinol. 2012;351(2):269‐278. doi:10.1016/j.mce.2011.12.017.

Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev. 2007;29:88‐97. doi:10.1093/epirev/mxm006.

Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1262‐1269. doi:10.1158/1055-9965.EPI-04-0371.

Severi G, Morris HA, MacInnis RJ, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(1):86‐91. doi:10.1158/1055-9965.EPI-05-0633.

Hursting SD, Digiovanni J, Dannenberg AJ, et al. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res (Phila). 2012;5(11):1260‐1272. doi:10.1158/1940-6207.CAPR-12-0140.

Lee CH, Woo YC, Wang Y, Yeung CY, Xu A, Lam KS. Obesity, adipokines and cancer: an update. Clin Endocrinol (Oxf). 2015;83(2):147‐156. doi:10.1111/cen.12667.

Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547‐594. doi:10.1210/er.2011-1015.

Liu LY, Wang M, Ma ZB, et al. The role of adiponectin in breast cancer: a meta-analysis. PLoS One. 2013;8(8):e73183. doi:10.1371/journal.pone.0073183.

Katira A, Tan PH. Evolving role of adiponectin in cancer-controversies and update. Cancer Biol Med. 2016;13(1):101‐119. doi:10.28092/j.issn.2095-3941.2015.0092.

Liao LM, Weinstein SJ, Pollak M, et al. Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. Carcinogenesis. 2013;34(1):109‐112. doi:10.1093/carcin/bgs322.

Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014;20(28):9330‐9337. doi:10.3748/wjg.v20.i28.9330.

Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354(22):2340‐2348. doi:10.1056/NEJMoa054391.

Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA. 2013;310(6):627‐636. doi:10.1001/jama.2013.226450.

Maclure KM, Hayes KC, Colditz GA, Stampfer MJ, Speizer FE, Willett WC. Weight, diet, and the risk of symptomatic gallstones in middle-aged women. N Engl J Med. 1989;321(9):563‐569. doi:10.1056/NEJM198908313210902.

Espinoza JA, Bizama C, García P, et al. The inflammatory inception of gallbladder cancer. Biochim Biophys Acta. 2016;1865(2):245‐254. doi:10.1016/j.bbcan.2016.03.004.